Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study. Magne F, Cellerino M, Balletto E, Aluan K, et al. Mult Scler 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.

Read + Share

Amedeo Smart

Independent Medical Education

Magne F, Cellerino M, Balletto E, Aluan K, et al. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study. Mult Scler 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
PMID: 35762136